The world industry for bioproduction of cell therapy by 2025

DUBLIN,, February 23, 2021 / PRNewswire / – Report “Bioproduction of Cell Therapy: Global Markets” added to report’s offer.

This research report presents a detailed analysis of the global market for cell therapy bioproduction by product type, application, and region. The report discusses key growth inhibitors of bioproduction of cell therapy. The report discusses the role of actors in the supply chain from producers to researchers. The report analyzes key companies operating in the global market for cell therapy bioproduction. A detailed analysis of the patents in the report will provide insight into existing and upcoming technological trends.

In this report, the market for cell therapy bioproduction is segmented by product type, application, and region. Based on the type of product, the market is segmented into cell source (T-cells, dendritic cells, tumor cells and stem cells) and type of therapy (autologous cell therapies, allogeneic cell therapies). The market according to applications is categorized into cardiovascular diseases, bone repair, neurological disorders, skeletal muscle repair, cancer and others. The market is segmented by region North America,, Europe,, Asia-Pacific and RED.

The report includes:

  • 23 tables
  • An overview of global markets for cell therapy bioproduction
  • Market size assessment and analysis of global market trends with data from 2019, 2020 and projections of complex annual growth rates (CAGR) until 2025.
  • Assess market dynamics such as drivers, constraints, opportunities, and identify areas that inhibit growth affecting the global market
  • Detailed description of allogeneic (third party donor cells) and autologous (own body cells) cell therapy and analysis of its advantages and limitations
  • Information on clinical trials of cell therapy; insight into regulatory scenarios and initiatives of government organizations
  • Assessment of current market trends, market size, market forecasting and technological progress in the industry
  • Analysis of the market share of key companies in the industry and coverage of events such as mergers and acquisitions, joint ventures, collaborations or partnerships and other key market strategies; and relevant patent analysis
  • Company profiles of major players in the industry, including Bristol-Myers Squibb Co., Caladrius Biosciences Inc., Lonza Group Ltd., Merck KGaA and Novartis AG

There are a number of indications that can be cured with the help of cell therapies, and the number of therapeutic applications is expected to increase. Some of the indications that are being investigated for treatment with cell therapy are cerebral disorders such as Parkinson’s disease and Alzheimer’s disease, and cardiovascular disease. Cardiovascular diseases could be treated with cell therapies aimed at restoring normal heart function. Moreover, much research is underway to improve safety and efficacy in the treatment of various malignancies. Cell therapy can also be used to treat metabolic disorders such as type 1 diabetes mellitus, where the patient lacks insulin production. Researchers are also trying to restore normal liver and kidney function by introducing modified cells of appropriate origin.

Cell therapy is also a promising technique for the treatment of orthopedic, oncological, neurological and autoimmune diseases. Increasing the potential of cell therapy in the treatment of lung-related diseases using stem cell therapies is expected to be a major driver of market growth. Another driver is an improved understanding of the role of stem cells in inducing the development of functional lung cells, both from embryonic stem cells (ESCs) and from induced pluripotent stem cells (iPS). Stem cell therapy provides further understanding of lung biology and repair after lung injury.

Increasing the incidence of cardiovascular disease, increasing demand for chimeric antigen receptor (CAR) therapy, and further developing access to stem cell therapy are leading to market growth. However, market constraints include bottlenecks faced by manufacturers during the commercialization of cell therapies and the high costs associated with cell therapies. The growth of allogeneic cell therapy is expected to stimulate market growth. Allogeneic cell therapy includes chemotherapy conditioning therapy followed by transplantation of hematopoietic stem cells as well as lymphocytes isolated from allogeneic healthy donors for the treatment of various chronic diseases. (Allogene means from “one person to another”, as opposed to autologous, meaning “from one person back to the same person after processing.”)

Hematopoietic stem cell transplantation is used to treat various blood cancers and hematological conditions. This transplant is the most commonly used cell therapy procedure.

Key topics:

Chapter 1 Introduction

  • Goals and objectives of the study
  • Reasons for conducting this study
  • Scope of the report
  • Methodology
  • Market estimates
  • Sources of information
  • Primary research
  • Secondary research
  • Geographical breakdown
  • Credentials of analysts
  • Custom research
  • Related reports

Chapter 2 Summary and key information

Chapter 3 Market and technology background

  • Introduction to bioproduction of cell therapy
  • What is cell therapy?
  • Stem cell transplantation
  • Autologous
  • Allogeneic
  • Syngeneic
  • Bioproduction and stem cell classification
  • Based on the ability to distinguish
  • Based on the source
  • Classification of cell therapy technology
  • Somatic Cell Technologies
  • Three-dimensional technologies
  • Cell immortalization technologies
  • Genome Editing Technologies
  • Cellular plasticity technologies
  • Ex vivo modification of cell genes using viral vector technologies
  • In vivo modification of cell genes using viral vector technologies
  • Stem cell applications
  • Mechanism of cell therapy
  • Method of delivery of cell therapy
  • Development of a model of cell therapy
  • The role of contract makers
  • Clinical trials in progress
  • A network of clinical trials focused on stem cell therapy

Chapter 4 Market Trends and Challenges

  • Challenges
  • Drivers
  • Restrictions
  • Opportunity

Chapter 5 Market analysis by product type

  • Type of therapy
  • Cell source
  • Increased demand for chimeric antigen receptor (CAR) T cell therapy

Chapter 6 Market analysis by applications

  • Cardiovascular diseases
  • Imitation of microparticle cells
  • Bone repair
  • Neurological disorders
  • Spinal cord injury
  • Stroke
  • Parkinson’s disease
  • Amyotrophic lateral sclerosis
  • Multiple sclerosis
  • Cerebral palsy
  • Alzheimer’s disease
  • Vision restoration
  • Spine repair
  • Batten’s disease
  • Skeletal muscle repair
  • Internal healing mechanisms
  • Mechanism of cell therapy
  • Cancer
  • Other diseases

Chapter 7 Market Analysis by Region

  • Market overview
  • North America
  • USA
  • Canada
  • Mexico
  • Europe
  • Cardiovascular diseases in Europe
  • Factors contributing to cardiovascular disease (CVD)
  • Germany
  • UK
  • France
  • Asia-Pacific
  • china
  • India
  • Japan
  • The rest of the APAC
  • The rest of the world
  • south america
  • middle east i Africa

Chapter 8 Regulatory structure

  • FDA approvals
  • Cell therapy for CBER regulations
  • Federal Regulation Codes
  • A collection of cells
  • Code of regulations
  • Laws governing the use of stem cell treatments
  • EU Regulatory status determination
  • Regulatory scenario in India

Chapter 9 Company profiles

  • Bone Therapeutics Sa
  • Bristol-Myers Squibb Co.
  • Caladrius Biosciences Inc.
  • Cell Therapies Pty Ltd.
  • Cellular Biomedicine Group Inc.
  • Iovance Biotherapeutics Inc.
  • Lonza Group Ltd.
  • Merck Kgaa
  • Neurogeneration Inc.
  • Novartis Ag
  • Regen Biopharma Inc.
  • Regeneus Ltd.

Chapter 10 Appendix: References

For more information on this report, visit

Media contact:

Research and markets
Laura Wood, Senior Manager
[email protected]

For EST business hours, call + 1-917-300-0470
For a free call from the US / CAN + 1-800-526-8630
For GMT opening hours call + 353-1-416-8900

American Fax: 646-607-1907
Fax (outside the US): + 353-1-481-1716

SOURCE Research and Markets

Related links